Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults

HIV Med. 2010 Sep;11(8):535-9. doi: 10.1111/j.1468-1293.2010.00830.x. Epub 2010 Apr 13.

Abstract

Objectives: The acquisition of adequate vaccine-induced humoral immunity is especially important in HIV-infected individuals, who are at increased risk of infections. The aim of the study was to assess the safety of administering a complete vaccination programme to successfully treated HIV-infected adults and to evaluate specific humoral responses and the effect of highly active antiretroviral therapy (HAART) interruption on these responses.

Methods: A placebo-controlled, double-blind clinical trial was designed and 26 HIV-infected adults enrolled. Study participants were randomized to receive either a complete immunization schedule with commercial vaccines or placebo for 12 months. HAART was then discontinued for 6 months. Specific humoral responses were evaluated at baseline, at month 12 and after HAART interruption and compared between groups.

Results: There were neither local nor systemic secondary effects related to vaccination. Specific humoral responses to vaccines were adequate, but a loss of immunoglobulin G titres was observed after HAART interruption in 12 study participants.

Conclusions: HAART interruption may cause impairment of previously acquired vaccine-induced immunity in HIV-infected adults.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / administration & dosage*
  • Anti-Retroviral Agents / immunology
  • Antibodies, Viral / immunology
  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV-1*
  • Humans
  • Immunoglobulin G / blood
  • Male
  • Middle Aged
  • Placebos
  • Vaccination
  • Viral Load
  • Viral Vaccines / immunology*

Substances

  • Anti-Retroviral Agents
  • Antibodies, Viral
  • Immunoglobulin G
  • Placebos
  • Viral Vaccines